411 related articles for article (PubMed ID: 36185807)
1. Immunotherapy approaches for the treatment of diffuse midline gliomas.
Bernstock JD; Hoffman SE; Kappel AD; Valdes PA; Essayed W; Klinger NV; Kang KD; Totsch SK; Olsen HE; Schlappi CW; Filipski K; Gessler FA; Baird L; Filbin MG; Hashizume R; Becher OJ; Friedman GK
Oncoimmunology; 2022; 11(1):2124058. PubMed ID: 36185807
[TBL] [Abstract][Full Text] [Related]
2. GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas.
Majzner RG; Ramakrishna S; Yeom KW; Patel S; Chinnasamy H; Schultz LM; Richards RM; Jiang L; Barsan V; Mancusi R; Geraghty AC; Good Z; Mochizuki AY; Gillespie SM; Toland AMS; Mahdi J; Reschke A; Nie EH; Chau IJ; Rotiroti MC; Mount CW; Baggott C; Mavroukakis S; Egeler E; Moon J; Erickson C; Green S; Kunicki M; Fujimoto M; Ehlinger Z; Reynolds W; Kurra S; Warren KE; Prabhu S; Vogel H; Rasmussen L; Cornell TT; Partap S; Fisher PG; Campen CJ; Filbin MG; Grant G; Sahaf B; Davis KL; Feldman SA; Mackall CL; Monje M
Nature; 2022 Mar; 603(7903):934-941. PubMed ID: 35130560
[TBL] [Abstract][Full Text] [Related]
3. Dual IGF1R/IR inhibitors in combination with GD2-CAR T-cells display a potent anti-tumor activity in diffuse midline glioma H3K27M-mutant.
de Billy E; Pellegrino M; Orlando D; Pericoli G; Ferretti R; Businaro P; Ajmone-Cat MA; Rossi S; Petrilli LL; Maestro N; Diomedi-Camassei F; Pezzullo M; De Stefanis C; Bencivenga P; Palma A; Rota R; Del Bufalo F; Massimi L; Weber G; Jones C; Carai A; Caruso S; De Angelis B; Caruana I; Quintarelli C; Mastronuzzi A; Locatelli F; Vinci M
Neuro Oncol; 2022 Jul; 24(7):1150-1163. PubMed ID: 34964902
[TBL] [Abstract][Full Text] [Related]
4. The intrinsic and microenvironmental features of diffuse midline glioma: Implications for the development of effective immunotherapeutic treatment strategies.
Persson ML; Douglas AM; Alvaro F; Faridi P; Larsen MR; Alonso MM; Vitanza NA; Dun MD
Neuro Oncol; 2022 Sep; 24(9):1408-1422. PubMed ID: 35481923
[TBL] [Abstract][Full Text] [Related]
5. Potent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M
Mount CW; Majzner RG; Sundaresh S; Arnold EP; Kadapakkam M; Haile S; Labanieh L; Hulleman E; Woo PJ; Rietberg SP; Vogel H; Monje M; Mackall CL
Nat Med; 2018 May; 24(5):572-579. PubMed ID: 29662203
[TBL] [Abstract][Full Text] [Related]
6. HER2 chimeric antigen receptor T cell immunotherapy is an effective treatment for diffuse intrinsic pontine glioma.
Wang SS; Davenport AJ; Iliopoulos M; Hughes-Parry HE; Watson KA; Arcucci V; Mulazzani M; Eisenstat DD; Hansford JR; Cross RS; Jenkins MR
Neurooncol Adv; 2023; 5(1):vdad024. PubMed ID: 37152812
[TBL] [Abstract][Full Text] [Related]
7. A phase I/II study of ribociclib following radiation therapy in children with newly diagnosed diffuse intrinsic pontine glioma (DIPG).
DeWire M; Fuller C; Hummel TR; Chow LML; Salloum R; de Blank P; Pater L; Lawson S; Zhu X; Dexheimer P; Carle AC; Kumar SS; Drissi R; Stevenson CB; Lane A; Breneman J; Witte D; Jones BV; Leach JL; Fouladi M
J Neurooncol; 2020 Sep; 149(3):511-522. PubMed ID: 33034839
[TBL] [Abstract][Full Text] [Related]
8. TIM-3 blockade in diffuse intrinsic pontine glioma models promotes tumor regression and antitumor immune memory.
Ausejo-Mauleon I; Labiano S; de la Nava D; Laspidea V; Zalacain M; Marrodán L; García-Moure M; González-Huarriz M; Hervás-Corpión I; Dhandapani L; Vicent S; Collantes M; Peñuelas I; Becher OJ; Filbin MG; Jiang L; Labelle J; de Biagi-Junior CAO; Nazarian J; Laternser S; Phoenix TN; van der Lugt J; Kranendonk M; Hoogendijk R; Mueller S; De Andrea C; Anderson AC; Guruceaga E; Koschmann C; Yadav VN; Gállego Pérez-Larraya J; Patiño-García A; Pastor F; Alonso MM
Cancer Cell; 2023 Nov; 41(11):1911-1926.e8. PubMed ID: 37802053
[TBL] [Abstract][Full Text] [Related]
9. Oncolytic virotherapy for the treatment of pediatric brainstem gliomas.
Gállego Pérez-Larraya J; García-Moure M; Alonso MM
Rev Neurol (Paris); 2023 Jun; 179(5):475-480. PubMed ID: 37061388
[TBL] [Abstract][Full Text] [Related]
10. Anti-tumor efficacy of anti-GD2 CAR NK-92 cells in diffuse intrinsic pontine gliomas.
Zuo P; Li Y; He C; Wang T; Zheng X; Liu H; Wu Z; Zhang J; Liao X; Zhang L
Front Immunol; 2023; 14():1145706. PubMed ID: 37251413
[TBL] [Abstract][Full Text] [Related]
11. CAR T-cell therapy: a potential treatment strategy for pediatric midline gliomas.
Das AK; Sinha M; Singh SK; Chaudhary A; Boro AK; Agrawal M; Bhardwaj S; Kishore S; Kumari K
Acta Neurol Belg; 2024 Apr; ():. PubMed ID: 38669002
[TBL] [Abstract][Full Text] [Related]
12. Epidemiology, Diagnostic Strategies, and Therapeutic Advances in Diffuse Midline Glioma.
Miguel Llordes G; Medina Pérez VM; Curto Simón B; Castells-Yus I; Vázquez Sufuentes S; Schuhmacher AJ
J Clin Med; 2023 Aug; 12(16):. PubMed ID: 37629304
[No Abstract] [Full Text] [Related]
13. Progress in diffuse intrinsic pontine glioma: advocating for stereotactic biopsy in the standard of care.
Williams JR; Young CC; Vitanza NA; McGrath M; Feroze AH; Browd SR; Hauptman JS
Neurosurg Focus; 2020 Jan; 48(1):E4. PubMed ID: 31896081
[TBL] [Abstract][Full Text] [Related]
14. Diffuse Intrinsic Pontine Glioma: From Diagnosis to Next-Generation Clinical Trials.
Vitanza NA; Monje M
Curr Treat Options Neurol; 2019 Jul; 21(8):37. PubMed ID: 31290035
[TBL] [Abstract][Full Text] [Related]
15. Developing chemotherapy for diffuse pontine intrinsic gliomas (DIPG).
Gwak HS; Park HJ
Crit Rev Oncol Hematol; 2017 Dec; 120():111-119. PubMed ID: 29198324
[TBL] [Abstract][Full Text] [Related]
16. Preclinical evaluation of convection-enhanced delivery of liposomal doxorubicin to treat pediatric diffuse intrinsic pontine glioma and thalamic high-grade glioma.
Sewing ACP; Lagerweij T; van Vuurden DG; Meel MH; Veringa SJE; Carcaboso AM; Gaillard PJ; Peter Vandertop W; Wesseling P; Noske D; Kaspers GJL; Hulleman E
J Neurosurg Pediatr; 2017 May; 19(5):518-530. PubMed ID: 28291423
[TBL] [Abstract][Full Text] [Related]
17. Exploiting 4-1BB immune checkpoint to enhance the efficacy of oncolytic virotherapy for diffuse intrinsic pontine gliomas.
Laspidea V; Puigdelloses M; Labiano S; Marrodán L; Garcia-Moure M; Zalacain M; Gonzalez-Huarriz M; Martínez-Vélez N; Ausejo-Mauleon I; de la Nava D; Herrador-Cañete G; Marco-Sanz J; Guruceaga E; de Andrea CE; Villalba M; Becher O; Squatrito M; Matía V; Gállego Pérez-Larraya J; Patiño-García A; Gupta S; Gomez-Manzano C; Fueyo J; Alonso MM
JCI Insight; 2022 Apr; 7(7):. PubMed ID: 35393952
[TBL] [Abstract][Full Text] [Related]
18. Current perspectives on diffuse midline glioma and a different role for the immune microenvironment compared to glioblastoma.
Pachocki CJ; Hol EM
J Neuroinflammation; 2022 Nov; 19(1):276. PubMed ID: 36403059
[TBL] [Abstract][Full Text] [Related]
19. Real-time drug testing of paediatric diffuse midline glioma to support clinical decision making: The Zurich DIPG/DMG centre experience.
Mueller T; Laternser S; Guerreiro Stücklin AS; Gerber NU; Mourabit S; Rizo M; Rushing EJ; Kottke R; Grotzer M; Krayenbühl N; Nazarian J; Mueller S
Eur J Cancer; 2023 Jan; 178():171-179. PubMed ID: 36455411
[TBL] [Abstract][Full Text] [Related]
20. Pediatric Diffuse Midline Gliomas: An Unfinished Puzzle.
Di Ruscio V; Del Baldo G; Fabozzi F; Vinci M; Cacchione A; de Billy E; Megaro G; Carai A; Mastronuzzi A
Diagnostics (Basel); 2022 Aug; 12(9):. PubMed ID: 36140466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
